Clinical trials: Ventricular Remodeling
Ischemic Heart Disease, Myocardial Infarction
Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT to Predict Left Ventricular Remodelling in Patients Reperfused in the Acute Phase of MI
Left myocardial infarction (MI), has a negative impact of long term morbidity and mortality. Even in patients treated successfully by angioplasty in the acute phase of infarct, the remodelling is observed in approximately 30% of…
- Trial name
- NCT00487812
- Testing
- Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Mitral Regurgitation (MR)
Quantification of Mitral Regurgitation Using 4D MRI Flow : Comparison With 2D MRI Flow and Echocardiography Using the Evolution of Left Ventricular Remodeling as a Reference
The goal of this study is to evaluate whether 4D MRI provides a better assessment of mitral regurgitation quantification and associated ventricular remodeling than standard imaging techniques: echocardiography and 2D MRI, in…
- Trial name
- FLAME (NCT07066904)
- Testing
- Standard echocardiography, 2D phase-contrast magnetic resonance imaging, 4D flow magnetic resonance imaging
- Where
- 3 sites in France
- Volunteers
- 160 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Coronary Syndrome
Study on Prediction of Left Ventricular Remodeling Using ST2
Patients who underwent percutaneous coronary intervention after diagnosis of acute coronary syndrome should be enrolled in the study and follow - up.
- Trial name
- TRUSTED (NCT03841214)
- Where
- South Korea
- Volunteers
- 114 people
- Sponsor
- Keimyung University Dongsan Medical Center
Tetralogy of Fallot With Pulmonary Stenosis
Right and Left Ventricle Remodeling Predictors After Pulmonary Valve Replacement in Patients With Repaired Tetralogy of Fallot
Long term survival of patients with repaired tetralogy of Fallot is excellent (about 85% at 35 year-old). However these patients are exposed to residual pulmonary stenosis (PS) and/or pulmonary regurgitation (PR).
- Trial name
- NCT02186691
- Testing
- MRI
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Tricuspid Regurgitation, Right Ventricular Dilatation
Pharmacological Reduction of Right Ventricular Enlargement
Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart failure (HF), mitral valve (MV) disease or atrial fibrillation.
- Trial name
- PROVE (NCT04345796)
- Testing
- Carvedilol+Empagliflozin, Carvedilol, Empagliflozin
- Where
- 3 sites in South Korea
- Volunteers
- 56 people
- Sponsor
- Asan Medical Center
Recent Acute Myocardial Infarction
Impact of the Obstructive Sleep Apnea Syndrome (OSAS) on the Ventricular Remodeling After Acute Myocardial Infarction
Coronary artery disease is a common and serious disease, the leading cause of death worldwide. Obstructive sleep apnea syndrome (OSAS) is common and often under-diagnosed in coronary artery disease where it could be involved in…
- Trial name
- SAS-IDM (NCT02439294)
- Testing
- Without Obstructive Sleep Apnea (syndrome), Mild or moderate Obstructive Sleep Apnea (syndrome), Severe Obstructive Sleep Apnea (syndrome)
- Where
- France
- Volunteers
- 67 people
- Sponsor
- University Hospital, Montpellier
Cardiac Pacing, Artificial, Tricuspid Valve Regurgitation, Non-rheumatic
Cardiac Implantable Electronic Device- Induced Remodelling of Tricuspid Valve and Right Chambers
This single-center longitudinal study aims to evaluate the occurrence and clinical impact of tricuspid regurgitation (TR) after cardiac-implanted-electronic-device (CIED) implantation by comprehensive echocardiographic…
- Trial name
- CIED-REMTRIC (NCT06914570)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Istituto Auxologico Italiano
Heart Failure
REmodeling the Left Ventricle With Atrial Modulated Pacing
New therapy tested in heart failure with preserved ejection fraction (HFpEF) patients with approved indications for pacing to determine if elevated pacing therapy is tolerated and whether there is a signal for efficacy.
- Trial name
- REVAMP (NCT03210402)
- Testing
- Elevated night pacing on, Elevated night pacing off
- Where
- 10 sites in United States
- Volunteers
- 22 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Left Ventricular Remodeling, Medication Adherence
IMproving reModeling in Acute myoCardial Infarction Using Live and Asynchronous TElemedicine.
The proposed research aims to compare Left ventricular remodeling outcomes among patients with AMI and elevated NT-pro-B-type natriuretic peptide receiving telemedicine-guided post-MI treatment vs.
- Conditions
- Left Ventricular Remodeling, Medication Adherence, Acute Coronary Syndrome
- Trial name
- IMMACULATE (NCT02468349)
- Testing
- Telemedicine
- Where
- 3 sites in Singapore
- Volunteers
- 300 people
- Sponsor
- National University Heart Centre, Singapore
Heart Failure, Congestive
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with a lower dose of an ACE inhibitor is more effective in reverse left ventricular remodeling in severe…
- Trial name
- NCT00125437
- Testing
- spironolactone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hebei Medical University
Cardiomyopathies, Pediatric ALL
Ventricular Remodelling and Metabolomics in Pediatric Cardiomyopathies (PROGRESS-OMICS)
The pathogenesis of cardiomyopathies is complex and a simple approach cannot describe the whole picture. Different etiologies are reported in pediatric age and heart failure onset can lead to poor prognosis in term of need of…
- Trial name
- PRO-OMICS (NCT04670731)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bambino Gesù Hospital and Research Institute
Congestive Heart Failure, Mitral Regurgitation
Speckle Tracking Imaging and Realtime 3 Dimensional Echocardiograhy to Study LV Function and Remodeling After Acute Myocardial Infarction (AMI)
Left ventricular (LV) remodeling after acute myocardial infarction (AMI) has been well described in previous studies. However, there is a paucity of data on the incidence of and risk factors for LV remodeling in modern clinical…
- Trial name
- NCT00745680
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Heart Failure, Congestive
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
- Trial name
- REMODEL (NCT00082589)
- Testing
- Eplerenone
- Where
- 53 sites in United States
- Volunteers
- 250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Myocardial Infarction
High-Intensity Interval Training Early After Left Ventricular Myocardial Infarction
Several studies have shown that high-intensity interval training (HIIT) is more effective than moderate-intensity continuous exercise training (MICE) at improving functional capacity and quality of life in stable cardiac patients…
- Trial name
- HIIT-EARLY (NCT02627586)
- Testing
- HIIT, MICE
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Hypertrophy, Left Ventricular
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure
This study will assess the efficacy of mirabegron, a new beta3-adrenergic receptor in the prevention of heart failure. This is a two armed, prospective, randomized, placebo-controlled, multi-centric european phase IIb trial with…
- Trial name
- Beta3_LVH (NCT02599480)
- Testing
- mirabegron, Echocardiography, Cardiac MRI
- Where
- 10 sites in Belgium, France and 6 more
- Volunteers
- 296 people
- Sponsor
- Jean-Luc Balligand
COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
Long COVID or Postacute sequelae of COVID-19 infection (PASC) are increasingly recognised complications, defined by lingering symptoms, not present prior to the infection, typically persisting for more than 4 weeks.
- Conditions
- COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle, Remodeling, Vascular, Left Ventricular Dysfunction
- Trial name
- MYOFLAME-19 (NCT05619653)
- Testing
- Prednisolone, Losartan
- Where
- 5 sites in Austria, Germany
- Volunteers
- 279 people
- Sponsor
- Valentina Puentmann
Bradycardia, Heart Failure
LEft Bundle branchArea Pacing to Avoid Pacing-induced CARdiomyopathy
LEAP-CAR will evaluate the benefit of left bundle branch area pacing (LBBAP), comparing to conventional right ventricular pacing (RVP), in preventing pacing-induced cardiomyopathy (PICM) in patients undergoing pacemaker implant…
- Conditions
- Bradycardia, Heart Failure, Pacemaker-Induced Cardiomyopathy, Conduction Block, Atrioventricular
- Trial name
- LEAP-CAR (NCT05910866)
- Testing
- Left bundle branch area pacing (LBBAP), Right ventricular pacing (RVP)
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Heart Failure
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Prior to reperfusion therapy, the major therapeutic breakthrough in myocardial infarction was the demonstration that ACE inhibitors or ARBs, given to prevent adverse "remodelling" (progressive dilatation and decline in systolic…
- Trial name
- RECOVER-LV (NCT03552575)
- Testing
- sacubitril/valsartan, Valsartan
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people
- Sponsor
- NHS Greater Glasgow and Clyde
Myocardial Infarction, Ventricular Remodeling
Disparities in Myocardial Infarction Remodeling According to Gender
Following myocardial infarction, female individuals demonstrate a poorer prognosis, characterized by elevated rates of mortality and heart failure. A primary hypothesis suggests unfavorable cardiac remodeling in women.
- Trial name
- REMOVE 2 (NCT06343844)
- Testing
- cardiac imaging to assess left ventricular volumes and function
- Where
- France
- Volunteers
- 1,650 people
- Sponsor
- University Hospital, Angers
Acromegaly Cardiomyopathy
Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy
Pathophysiology of acromegaly cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several models of…
- Trial name
- SUM (NCT02611336)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Andrea M. Isidori